Moneywise
Peter Thiel is betting big on a $2B AI cow collar startup powered by cowgorithms — and investors are fighting to get in
📈
AI Sentiment
Highly Positive
9/10
- Home
- MRK
as of 03-23-2026 1:25pm EST
$115.39
+$1.72
+1.51%
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | RAHWAY |
| Market Cap: | 268.7B | IPO Year: | 1994 |
| Target Price: | $124.64 | AVG Volume (30 days): | 7.3M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 7.28 | EPS Growth: | 8.01 |
| 52 Week Low/High: | $75.40 - $125.14 | Next Earning Date: | 04-23-2026 |
| Revenue: | $65,011,000,000 | Revenue Growth: | 1.31% |
| Revenue Growth (this year): | 3.74% | Revenue Growth (next year): | 5.47% |
| P/E Ratio: | 15.61 | Index: | |
| Free Cash Flow: | 12.4B | FCF Growth: | -31.70% |
AI-Powered MRK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 18 hours ago
AI Recommendation
hold
Model Accuracy: 77.38%
77.38%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Merck & Company Inc. (new) (MRK)
Guindo Chirfi
Sell
Chief Marketing Officer
MRK Feb 12, 2026
Avg Cost/Share
$121.46
Shares
10,000
Total Value
$1,214,562.00
Owned After
60,615.127
SEC Form 4
Zachary Jennifer
Sell
EVP, General Counsel
MRK Feb 9, 2026
Avg Cost/Share
$119.15
Shares
121,573
Total Value
$14,485,690.41
Owned After
68,915.671
Guindo Chirfi
Sell
Chief Marketing Officer
MRK Feb 9, 2026
Avg Cost/Share
$118.41
Shares
10,000
Total Value
$1,184,101.00
Owned After
60,615.127
SEC Form 4
Williams David Michael
Sell
EVP,Chief Info&Digital Officer
MRK Feb 6, 2026
Avg Cost/Share
$121.91
Shares
5,000
Total Value
$609,525.00
Owned After
30,837.743
SEC Form 4
Oosthuizen Johannes Jacobus
Sell
President, U.S. Market
MRK Feb 6, 2026
Avg Cost/Share
$121.87
Shares
15,000
Total Value
$1,827,991.50
Owned After
21,197.389
SEC Form 4
DeLuca Richard R.
Sell
EVP&Pres, Merck Animal Heallth
MRK Feb 6, 2026
Avg Cost/Share
$120.92
Shares
37,685
Total Value
$4,557,024.71
Owned After
160,173.834
SEC Form 4
Guindo Chirfi
Sell
Chief Marketing Officer
MRK Feb 5, 2026
Avg Cost/Share
$121.88
Shares
20,000
Total Value
$2,437,676.00
Owned After
60,615.127
SEC Form 4
Litchfield Caroline
Sell
EVP & CFO
MRK Feb 4, 2026
Avg Cost/Share
$119.61
Shares
41,997
Total Value
$5,023,311.57
Owned After
90,192.194
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Guindo Chirfi | MRK | Chief Marketing Officer | Feb 12, 2026 | Sell | $121.46 | 10,000 | $1,214,562.00 | 60,615.127 | |
| Li Dean Y | MRK | Executive VP & President, MRL | Feb 10, 2026 | Sell | $117.52 | 10,235 | $1,202,843.81 | 92,035.05 | |
| Zachary Jennifer | MRK | EVP, General Counsel | Feb 9, 2026 | Sell | $119.15 | 121,573 | $14,485,690.41 | 68,915.671 | |
| Guindo Chirfi | MRK | Chief Marketing Officer | Feb 9, 2026 | Sell | $118.41 | 10,000 | $1,184,101.00 | 60,615.127 | |
| Williams David Michael | MRK | EVP,Chief Info&Digital Officer | Feb 6, 2026 | Sell | $121.91 | 5,000 | $609,525.00 | 30,837.743 | |
| Oosthuizen Johannes Jacobus | MRK | President, U.S. Market | Feb 6, 2026 | Sell | $121.87 | 15,000 | $1,827,991.50 | 21,197.389 | |
| DeLuca Richard R. | MRK | EVP&Pres, Merck Animal Heallth | Feb 6, 2026 | Sell | $120.92 | 37,685 | $4,557,024.71 | 160,173.834 | |
| Guindo Chirfi | MRK | Chief Marketing Officer | Feb 5, 2026 | Sell | $121.88 | 20,000 | $2,437,676.00 | 60,615.127 | |
| Li Dean Y | MRK | Executive VP & President, MRL | Feb 4, 2026 | Sell | $118.77 | 15,087 | $1,791,824.15 | 92,035.05 | |
| Litchfield Caroline | MRK | EVP & CFO | Feb 4, 2026 | Sell | $119.61 | 41,997 | $5,023,311.57 | 90,192.194 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 3, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 3, 2026 · 100% conf.
AI Prediction BUY
1D
+1.03%
$117.03
Act: +2.13%
5D
+2.37%
$118.59
Act: +1.13%
20D
+0.84%
$116.82
Act: +3.81%
Price: $115.84 Prob +5D: 100% AUC: 1.000
0001104659-26-009495
false 0000310158
0000310158
2026-02-03 2026-02-03
0000310158
us-gaap:CommonStockMember
2026-02-03 2026-02-03
0000310158
mrk:Sec1.875NotesDue2026Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.250NotesDue2032Member
2026-02-03 2026-02-03
0000310158
mrk:Sec2.500NotesDue2034Member
2026-02-03 2026-02-03
0000310158
mrk:Sec1.375NotesDue2036Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.500NotesDue2037Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.700NotesDue2044Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.750NotesDue2054Member
2026-02-03 2026-02-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 3, 2026 (February 3, 2026)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
Registrant’s telephone number, including area code (908) 740-4000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
MRK/26
New York Stock Exchange
3.250% Notes due 2032
MRK/32
New York Stock Exchange
2.500% Notes due 2034
MRK/34
New York Stock Exchange
1.375% Notes due 2036
MRK 36A
New York Stock Exchange
3.500% Notes due 2037
MRK/37
New York Stock Exchange
3.700% Notes due 2044
MRK/44
New York Stock Exchange
3.750% Notes due 2054
MRK/54
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on February 3, 2026, regarding earnings for the fourth quarter and year end of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued February 3, 2026, regarding earnings for the fourth quarter and year end of 2025
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: February 3, 2026 By:
/s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 30, 2025
0001104659-25-103974
false 0000310158
0000310158
2025-10-30 2025-10-30
0000310158
us-gaap:CommonStockMember
2025-10-30 2025-10-30
0000310158
mrk:Sec1.875NotesDue2026Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.250NotesDue2032Member
2025-10-30 2025-10-30
0000310158
mrk:Sec2.500NotesDue2034Member
2025-10-30 2025-10-30
0000310158
mrk:Sec1.375NotesDue2036Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.500NotesDue2037Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.700NotesDue2044Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.750NotesDue2054Member
2025-10-30 2025-10-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 30, 2025 (October 30, 2025)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
Registrant’s telephone number, including area code (908) 740-4000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
MRK/26
New York Stock Exchange
3.250% Notes due 2032
MRK/32
New York Stock Exchange
2.500% Notes due 2034
MRK/34
New York Stock Exchange
1.375% Notes due 2036
MRK 36A
New York Stock Exchange
3.500% Notes due 2037
MRK/37
New York Stock Exchange
3.700% Notes due 2044
MRK/44
New York Stock Exchange
3.750% Notes due 2054
MRK/54
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on October 30, 2025, regarding earnings for the third quarter of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued October 30, 2025, regarding earnings for the third quarter of 2025
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: October 30, 2025 By:
/s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
2025 Q2 Q2 2025 Earnings
8-K Jul 29, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 29, 2025
0001104659-25-071380
false 0000310158
0000310158
2025-07-25 2025-07-25
0000310158
us-gaap:CommonStockMember
2025-07-25 2025-07-25
0000310158
mrk:Sec1.875NotesDue2026Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.250NotesDue2032Member
2025-07-25 2025-07-25
0000310158
mrk:Sec2.500NotesDue2034Member
2025-07-25 2025-07-25
0000310158
mrk:Sec1.375NotesDue2036Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.500NotesDue2037Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.700NotesDue2044Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.750NotesDue2054Member
2025-07-25 2025-07-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 29, 2025 (July 25, 2025)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
Registrant’s telephone number, including area code (732) 594-4000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
MRK/26
New York Stock Exchange
3.250% Notes due 2032
MRK/32
New York Stock Exchange
2.500% Notes due 2034
MRK/34
New York Stock Exchange
1.375% Notes due 2036
MRK 36A
New York Stock Exchange
3.500% Notes due 2037
MRK/37
New York Stock Exchange
3.700% Notes due 2044
MRK/44
New York Stock Exchange
3.750% Notes due 2054
MRK/54
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on July 29, 2025, regarding earnings for the second quarter of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 2.05. Costs Associated with Exit or Disposal Activities.
On July 25, 2025, the Company approved a new restructuring program (2025 Restructuring Program) designed to position the Company for its next chapter of growth and to successfully advance its pipeline and launch new products across multiple therapeutic areas. As part of this program, the Company expects to eliminate certain positions in sales and administrative organizations, as well as research and development. The Company will, however, continue to hire employees into new roles across all strategic growth areas of the business. In addition, the Company will reduce its global real estate footprint and continue to optimize its manufacturing network, aligning the geography of its global manufacturing footprint to its customers and reflecting changes in the Company’s business.
Most actions contemplated under the 2025 Restructuring Program are expected to be largely completed by the end of 2027, with the exception of certain manufacturing actions, which are expected to be substantially completed by the end of 2029. The cumulative pretax costs to
Latest Merck & Company Inc. (new) News
MRK Breaking Stock News: Dive into MRK Ticker-Specific Updates for Smart Investing
Simply Wall St.
Merck’s New GARDASIL Data And What It May Mean For MRK Stock
📈
AI Sentiment
Highly Positive
8/10
Financial Times
Big drugmakers saved at least $5bn on US taxes shifting income overseas
📉
AI Sentiment
Negative
3/10
Insider Monkey
H.C. Wainwright Raises Tempus AI (TEM) Price Target to $95
📈
AI Sentiment
Highly Positive
9/10
Benzinga
'My Dad Lost Everything': Jim Cramer 'Willing To Expose' His Father For Picking The Wrong Stock — And Missing Multimillionaire Opportunity
➖
AI Sentiment
Neutral
5/10
MarketBeat
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3
📊
AI Sentiment
Positive
7/10
Simply Wall St.
How The Investment Story For Merck KGaA (XTRA:MRK) Is Quietly Shifting On Cautious Targets
📊
AI Sentiment
Positive
6/10
Zacks
The Zacks Analyst Blog Highlights Merck, TotalEnergies and Union Pacific
📊
AI Sentiment
Positive
6/10
Compare MRK vs Leading Stocks
See how MRK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MRK Merck & Company Inc. (new) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.